HeartBeam Inc. (NASDAQ: BEAT) has reported its second-quarter 2026 financial and operational results, showcasing significant advancements in its heart attack detection program, the development of a 12-lead ECG extended wear patch, and the initial stages of commercial launch. These milestones underscore the company's commitment to addressing critical cardiac conditions through innovative technology.
The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, HeartBeam surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, indicating robust progress in validating its diagnostic capabilities. These studies are crucial for demonstrating the efficacy of HeartBeam's technology in detecting heart attacks, potentially leading to faster and more accurate diagnosis in various settings.
HeartBeam also unveiled a working prototype of its 12-lead ECG extended wear patch, a significant step towards offering continuous cardiac monitoring. The company has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the transition from development to market entry. This initial commercial activity is a key indicator of market acceptance and future revenue potential.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the prior year's net loss of $5 million, or $0.15 per share. As of June 30, 2026, the company held $8.8 million in cash, cash equivalents, and restricted cash. Importantly, HeartBeam expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, is projected to extend its cash runway into 2027. This financial stability provides the company with the necessary resources to continue its clinical and commercial endeavors without immediate capital constraints.
The implications of these developments are substantial. HeartBeam's technology, which collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG, has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis. This platform has the potential to redefine cardiac care by enabling portable, cable-free devices that deliver actionable heart intelligence outside medical facilities. Physicians could identify cardiac trends and acute conditions earlier, potentially improving patient outcomes and reducing healthcare costs.
As HeartBeam progresses with its clinical trials and commercial rollout, the successful execution of its strategies could position it as a leader in the cardiac diagnostics market. The company's focus on extending its cash runway into 2027 provides a buffer to achieve key milestones, such as presenting full ALIGN-ACS results at TCT 2026 and advancing the HEADSTART-ACS study. With over 20 issued patents, HeartBeam's intellectual property portfolio strengthens its competitive position.
Investors and stakeholders will be watching closely as HeartBeam continues to develop its technology and expand its commercial footprint. The company's ability to meet its clinical and commercial objectives will be critical in determining its long-term success and impact on cardiac care.
